X

Trial Profile

Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary)
Indications Astrocytoma; Glioma; Oligodendroglioma
Focus Therapeutic Use

Most Recent Events

19 Jan 2022 This trial has been completed in Greece, according to European Clinical Trials Database
18 Dec 2021 This trial has been completed in Portugal, according to European Clinical Trials Database.
18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com